IL6 and neoplasm: A related strategy is to alter the tumor milieu through druggable targets such as CXCR4, IL-6, IGF-1, VEGF, their cognate receptors, and RANKL (81) in combination therapy to target the cytokines involved in cell adhesion (82) has shown promise whereas monotherapy has been ineffective.